Live Feeds
● TRACKER Updated 16d ago · 9 sources tracked

US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

The US FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. This expands Mounjaro's use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients. Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Mounjaro (tirzepatide) is approved to reduce cardiovascular risk in adults with type 2 diabetes.
  • ✓ Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication.
  • ✓ The approval expands Mounjaro's use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients.
🛡️ Source Corroboration: 9 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The US FDA approved Mounjaro for a new indication, expanding its use to reduce cardiovascular risk in adults with type 2 diabetes.

Live updates

  1. US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

    The US FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. This expands Mounjaro's use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients. Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication.

    Why it matters

    This approval increases Eli Lilly's addressable patient pool and affects its competitive position in diabetes and cardiovascular disease treatment. Mounjaro's expanded use comes after previous approvals for blood sugar control. The drug's impact on the market and patients' treatment options will be closely watched.

    What is confirmed

    • Mounjaro (tirzepatide) is approved to reduce cardiovascular risk in adults with type 2 diabetes.
    • Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication.
    • The approval expands Mounjaro's use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients.

    What to watch next

    • The impact of Mounjaro's expanded use on Eli Lilly's market position and sales
    • Clinical trial data and real-world evidence on Mounjaro's cardiovascular benefits
    • Potential changes in treatment guidelines and recommendations for type 2 diabetes patients
    Sources used for this update (9)
    1. Reuters — US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
    2. qz.com — Eli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk
    3. Bloomberg.com — Lilly Diabetes Shot Mounjaro Wins US Approval for Heart Disease
    4. Eli Lilly and Company — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
    5. Fierce Pharma — Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
    6. USA Today — Eli Lilly's diabetes drug Mounjaro gets approval for a new use
    7. Time Magazine — Mounjaro Is Now Approved to Lower the Risk of Heart Events
    8. finance.yahoo.com — Why Is Eli Lilly (LLY) Getting A Bigger Role For Mounjaro?
    9. www.pharmexec.com — Editorial Podcasts
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community